Literature DB >> 20720387

Pyoderma gangrenosum of the eyelid: report of two cases and review of the literature.

N Saito1, T Yanagi, M Akiyama, H Y Lin, S Kasai, Y Fujita, N Yamane, D Inokuma, S Kase, K Ono, H Minakawa, H Shimizu.   

Abstract

Pyoderma gangrenosum (PG) of the eyelid is extremely rare, and its proper management is essential for the preservation of visual function. Here, we report 2 cases of PG of the eyelid with intraorbital involvement. In both cases, the skin and intraorbital lesions improved after systemic immunosuppressive therapies; however, corneal perforation occurred in 1 case. In order to assess the clinical features of PG of the eyelid and to obtain clues for optimal treatment, we reviewed 15 well-documented cases in the literature, including the present cases. Corneal perforation occurred in 4 cases and defective ocular motility in 1 case. Three patients eventually underwent enucleation of the affected eye. Our cases and the literature review clearly indicate that MRI is a powerful tool for evaluating the extent of extracutaneous PG lesions around the eye and that early diagnosis and immediate immunosuppressive therapy are crucial for the preservation of visual acuity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20720387     DOI: 10.1159/000317079

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  3 in total

1.  Retinal vasculitis associated with pyoderma gangrenosum: a case report.

Authors:  Nilay Yuksel; Sengul Ozdek
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-06-06

2.  Oral tacrolimus for ocular involvement in pediatric neutrophilic dermatoses.

Authors:  Caitlan Swaffar; Diana McShane; Paul Googe; Leonard Kovalick; Dean S Morrell; Eveline Y Wu
Journal:  JAAD Case Rep       Date:  2022-01-06

3.  Pyoderma gangrenosum of the eyelid associated with inflammatory bowel disease.

Authors:  Larissa A Habib; Natalie Wolkow; Liza Cohen; Lina Ma; Michael K Yoon; Nahyoung Grace Lee
Journal:  Am J Ophthalmol Case Rep       Date:  2020-03-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.